scholarly journals Role of microRNAs in the development of hepatocellular carcinoma and drug resistance

10.2741/4724 ◽  
2019 ◽  
Vol 24 (2) ◽  
pp. 382-391 ◽  
Author(s):  
Deepak Kumar
Keyword(s):  
Hepatocellular Carcinoma ◽  
Drug Resistance

scholarly journals The emerging role of microRNAs and long noncoding RNAs in drug resistance of hepatocellular carcinoma

2019 ◽  
Vol 18 (1) ◽  
Author(s):  
Ling Wei ◽  
Xingwu Wang ◽  
Liyan Lv ◽  
Jibing Liu ◽  
Huaixin Xing ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Drug Resistance ◽  
Human Cancer ◽  
Noncoding Rnas ◽  
Circular Rna ◽  
Long Noncoding Rnas ◽  
Protein Coding ◽  
Multiple Tumor ◽  
Nucleolar Rnas

Abstract Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide and the second most lethal human cancer. A portion of patients with advanced HCC can significantly benefit from treatments with sorafenib, adriamycin, 5-fluorouracil and platinum drugs. However, most HCC patients eventually develop drug resistance, resulting in a poor prognosis. The mechanisms involved in HCC drug resistance are complex and inconclusive. Human transcripts without protein-coding potential are known as noncoding RNAs (ncRNAs), including microRNAs (miRNAs), small nucleolar RNAs (snoRNAs), long noncoding RNAs (lncRNAs) and circular RNA (circRNA). Accumulated evidences demonstrate that several deregulated miRNAs and lncRNAs are important regulators in the development of HCC drug resistance which elucidates their potential clinical implications. In this review, we summarized the detailed mechanisms by which miRNAs and lncRNAs affect HCC drug resistance. Multiple tumor-specific miRNAs and lncRNAs may serve as novel therapeutic targets and prognostic biomarkers for HCC.

scholarly journals TIGAR Enhanced Free Ca2+ Concentration in Hepatocellular Carcinoma Cells to Accelerate the Sustained Proliferation and Drug Resistance

2021 ◽  
Author(s):  
Jia-ming Xie ◽  
Yi-qun Sui ◽  
Xin-yu Feng ◽  
Zhen-yu Feng ◽  
Wei Li ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Drug Resistance ◽  
Nuclear Factor Kappa B ◽  
Additional Treatment ◽  
Carcinoma Cells ◽  
Cell Counting ◽  
Nuclear Factor ◽  
Cysteine Proteinases ◽  
Hcc Cells

Abstract Background: To study the role of TP53-induced glycolysis and apoptosis regulator (TIGAR) in hepatocellular carcinoma (HCC) and drug resistance.Methods: HCC cells (HepG2 and SMMC7721) were used in this study. Fura 2-AM was used to assess cytosolic free Ca2+ concentrations ([Ca2+]i) within the two HCC cell lines. Nimodipine (NMDP), a Ca2+ antagonist, was used to reduce cytosolic [Ca2+]i level. Proliferation of HCC was measured using cell counting kit-8 (CCK-8). The roles of TIGAR and Ca2+ in drug resistance of HCC cells were assessed using epirubicin (Epi), 5-fluorouracil (5-FU), or cisplatinum (DDP).Results: Knockdown of TIGAR significantly suppressed cell viability, reduced [Ca2+]i, restrained protein expression of Ca2+-activated cysteine proteinases (Calpain1 and 2), as well as blocked the activation of nuclear factor kappa B (NF-κB) through an increase of cytoplasmic NF-κB and reduction of nuclear NF-κB. However, overexpression of TIGAR (oeTIGAR) resulted in the opposite. Evidence also shows that oeTIGAR suppressed the sensitivity of HCC to Epi, which was retarded by NMDP as an additional treatment. TIGAR interference could enhance the sensitivity of HCCs with high TIGAR expression to drugs.Conclusions: TIGAR promoted HCC progression and induced drug resistance, and the mechanism involved was [Ca2+]i-mediated activation of Calpain 1 and 2 and NF-κB signaling.

scholarly journals Role of MTDH, FOXM1 and microRNAs in Drug Resistance in Hepatocellular Carcinoma

Diseases ◽  
2014 ◽  
Vol 2 (3) ◽  
pp. 209-225 ◽  
Author(s):  
Xiangbing Meng ◽  
Eric Devor ◽  
Shujie Yang ◽  
Brandon Schickling ◽  
Kimberly Leslie
Keyword(s):  
Hepatocellular Carcinoma ◽  
Drug Resistance

scholarly journals The Role of RNA Methyltransferase METTL3 in Hepatocellular Carcinoma: Results and Perspectives

2021 ◽  
Vol 9 ◽  
Author(s):  
Fan Pan ◽  
Xin-Rong Lin ◽  
Li-Ping Hao ◽  
Xiao-Yuan Chu ◽  
Hai-Jun Wan ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Cell Proliferation ◽  
Drug Resistance ◽  
Rna Splicing ◽  
Tumor Invasion ◽  
Rapid Development ◽  
Rna Expression ◽  
Dependent Manner ◽  
Invasion And Metastasis

Hepatocellular carcinoma (HCC) is the 6th most prevalent cancer and the 4th leading cause of cancer-related death worldwide. Mechanisms explaining the carcinogenesis of HCC are not clear yet. In recent years, rapid development of N6-methyladenosine (m6A) modification provides a fresh approach to disclosing this mystery. As the most prevalent mRNA modification in eukaryotes, m6A modification is capable to post-transcriptionally affect RNA splicing, stability, and translation, thus participating in a variety of biological and pathological processes including cell proliferation, apoptosis, tumor invasion and metastasis. METTL3 has been recognized as a pivotal methyltransferase and essential to the performance of m6A modification. METTL3 can regulate RNA expression in a m6A-dependent manner and contribute to the carcinogenesis, tumor progression, and drug resistance of HCC. In the present review, we are going to make a clear summary of the known roles of METTL3 in HCC, and explicitly narrate the potential mechanisms for these roles.

Role of RAGE and its ligands S100A8/A9 in hepatocellular carcinoma onset and development

2015 ◽  
Vol 53 (01) ◽  
Author(s):  
AM De Ponti ◽  
D Schneller ◽  
T Pusterla ◽  
L Wiechert ◽  
T Longerich ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma
Sign in / Sign up

Export Citation Format

Share Document